The metabolisms of agaritine, a mushroom hydrazine in mice.

The mushroom hydrazine agaritine was measured in mouse plasma and urine using LC/MS/MS, which is highly specific. Agaritine concentration peaked 20 min after oral administration to mice (4.0 and 40 mg/kg). The concentration gradually decreased and returned to the basal level in 100 min. The maximum concentration, the time to the maximum concentration, and the half life were 0.37 microg/ml plasma, 0.33 h, and 0.71 h, respectively after administration of agaritine at 40 mg/kg body weight. One agaritine metabolite was found in the plasma and the urine from agaritine-administered mice. The structure of metabolites of agaritine by gamma-GT was next investigated using LC/MS. HMPH proved to be generated from agaritine. The oxidative stress marker 8-OHdG was detected in agaritine-administered mouse urine. After administration, the 8-OHdG level immediately tripled, and then decreased to the control level over 48 h. Its level then elevated again and remained high for 11 days. These results suggest that agaritine quickly metabolizes and disappears in the plasma, whereas DNA damage lasts for a long time after a single administration of agaritine to mice.

Urinary aldehydes as indicators of lipid peroxidation in vivo.

The excretion of malondialdehyde (MDA), lipophilic aldehydes and related carbonyl compounds in rat and human urine was investigated. MDA was found to be excreted mainly in the form of two adducts with lysine, indicating that its predominant reaction in vivo is with the lysine residues of proteins. Adducts with the phospholipid bases serine and ethanolamine and the nucleic acid bases guanine and deoxyguanosine also were found. Except for the adduct with deoxyguanosine (dG-MDA), the excretion of these compounds increased with peroxidative stress imposed in the form of vitamin E deficiency or the administration of iron or carbon tetrachloride. Marked differences in the concentration of dG-MDA in different tissues were correlated with their content of fatty acids having three or more double bonds, the putative source of MDA. Fourteen nonpolar and eleven polar lipophilic aldehydes and other carbonyl compounds were identified as their 2,4-diphenylhydrazine derivatives in rat urine. The excretion of five nonpolar and nine polar compounds was increased under conditions of peroxidative stress. The profile of lipophilic aldehydes obtained for human urine resembled that for rat urine. Except for a reported 4-hydroxynon-2-enal conjugate with mercapturic acid, the conjugated forms of the lipophilic aldehydes excreted in urine remain unidentified. Aldehyde excretion is influenced by numerous factors that affect the formation of lipid peroxides in vivo such as energy status, physical activity and environmental temperature, as well as by wide variations in the intake of peroxides in the diet. Consequently, urinalysis for aldehydic products of lipid peroxidation is an unreliable indicator of the general state of peroxidative stress in vivo.

Fate of the mushroom hydrazine agaritine in the rat and mouse.

The fate of the mushroom hydrazine [14C]agaritine was investigated in the mouse and rat strains previously employed in carcinogenicity studies with the edible mushroom Agaricus bisporus. Agaritine was rapidly absorbed in both species, achieving higher blood levels in the mouse, but with similar area under the curve. Covalent binding of agaritine material to proteins was detected only in the liver and kidney, but the extent of binding was the same in the rat and mouse. Most of the radioactivity was excreted during the first 24 hours in both animal species: in the rat it was distributed equally between urine and feces, whereas in the mouse more of the radioactivity was excreted in the urine. No qualitative differences in the metabolic profile were evident, but quantitative differences were observed. Treatment of the urine with deconjugating enzymes did not reveal the presence of any conjugates. Agaritine, N'-acetyl-4-(hydroxymethyl)phenylhydrazine, and 4-(hydroxymethyl)benzene diazonium ion were not detected in the urine or in the plasma of either species. No mutagens or promutagens were detected by the Ames mutagenicity assay in the urine of either species after exposure to agaritine. Repeated administration of agaritine to rats and mice did not alter the urinary metabolic profile and excretion of radioactivity. Similarly, feeding mice a raw mushroom diet, according to the protocol employed in the carcinogenicity studies, did not modulate the excretion of radioactivity or the urinary metabolic pattern. No major species differences in the fate of agaritine in rat and mouse were noted that could provide a rationale for the carcinogenicity of A. bisporus in the mouse, but not in the rat.

High-performance liquid chromatographic determination of glyoxylic acid in urine.

A high-performance liquid chromatographic (HPLC) method for the determination of urinary glyoxylic acid is proposed. The system is based on the precolumn derivatization of alpha-keto acids by means of phenylhydrazine, separation of the phenylhydrazone formed by HPLC and spectrophotometric detection at 324 nm. The method is precise and allows the determination of 0.5 mumol/l glyoxylate. The poor stability of glyoxylate under all conventional preservation conditions requires the analysis to be carried out as soon as possible after urine collection. Results of determinations on urine samples from healthy controls and from patients with idiopathic calcium stone disease and type I primary hyperoxaluria are reported.

Recovery of malondialdehyde in urine as a 2,4-dinitrophenylhydrazine derivative analyzed with high-performance liquid chromatography.

Malondialdehyde (MDA) in urine was measured as a 2,4-dinitrophenylhydrazine (DNPH) derivative using high-performance liquid chromatography (HPLC) for the analysis. MDA standard coeluted with a peak obtained from rat urine after i.p. administration of MDA standard. This peak was also the only peak containing 14C after injection of a [14C]MDA standard, and was shown by mass spectrometry to contain 1-(2,4-dinitrophenyl)pyrazole, the derivative formed when MDA is treated with DNPH. Depending on the amount given (0.3-5.5 mumol), the recovery (after 24 h sampling period) in urine was 0.7-2.6%. This apparent non-linear kinetics may relate to several factors, such as dose-dependent metabolism. However, the peak urinary concentration approached the expected plasma concentration and reproducible recovery data were obtained, suggesting that MDA was passively excreted in a reasonably stable form. These data indicate that monitoring MDA excretion in urine can give useful information about lipid peroxidation in vivo.

Recovery of malondialdehyde in urine as a 2,4-dinitrophenylhydrazine derivative after exposure to chloroform or hydroquinone.

Malondialdehyde (MDA) excretion in urine as an index for toxicological effects of chloroform and hydroquinone was evaluated. In a first series of experiments three groups of rats were used: non-pretreated rats (group I), starved rats (group II) and starved plus phenobarbital pretreated rats (group III). Chloroform (0.15 or 0.30 ml/kg, p.o.) was given as a single dose. The MDA excretion was related to the pretreatment, and in group III to liver damage. In a second series of experiments control rats were administered hydroquinone (100 or 200 mg/kg, p.o.), which induced a dose-related MDA excretion. These data indicate that the MDA assay was a selective and accurate marker for toxicological effects induced by the tested compounds.